A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia
Amir T. Fathi(University of Southern California), Philip C. Amrein(Massachusetts General Hospital), Robin Joyce(Beth Israel Deaconess Medical Center), Karen K. Ballen(University of Virginia Health System), David Avigan(Beth Israel Deaconess Medical Center), Christine Connolly(Massachusetts General Hospital), Gabriela Hobbs(Massachusetts General Hospital), Daniela Hernandez(Johns Hopkins University), Malgorzata McMasters(Beth Israel Deaconess Medical Center), Traci M. Blonquist(Harvard University), Ashley Perry(Harvard University), Tina T. Som(Harvard University), Emma Logan(Beth Israel Deaconess Medical Center), Mark J. Levis(Sidney Kimmel Cancer Center), Aura Y. Ramos(Harvard University), Donna Neuberg(Otsuka (Japan)), Christelle Joseph(Harvard University), Andrew M. Brunner(Harvard University)
Cited by 4